Rucaparib is FDA approved in patients with a BRCA mutation and who have received 2 more prior lines of previous chemotherapy.
Rachel Justus, PharmD, BCPS
Advertisement
Articles by Rachel Justus, PharmD, BCPS
Advertisement
Latest Updated Articles
The Role of PARP Inhibitors in Treating Ovarian CancerPublished: April 30th 2020 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Enlicitide Decanoate Data Show Significant LDL-C Reductions in At-Risk Patients
2
FDA Approves Tarlatamab-Dlle to Treat Adults With Extensive Stage Small Cell Lung Cancer
3
Newly Approved Specialty Drugs Advance Care for Inflammatory and Autoimmune Diseases
4
FDA Approves Sevabertinib for HER2-Mutant Non-Small Cell Lung Cancer
5
